Related Experiment Video
Updated: Aug 18, 2026

Influenza A Virus Studies in a Mouse Model of Infection
Published on: September 7, 2017
Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine
S E Robertson1, H P Traverso, J A Drucker
1Division of Immunization, Centers for Disease Control, Atlanta, Georgia.
Abstract:
The 1986-87 outbreak of paralytic poliomyelitis in Senegal, with 676 reported cases, provided an opportunity to evaluate the efficacy of an enhanced-potency inactivated poliovirus vaccine (N-IPV) in the Kolda region, where this vaccine has been used since 1980. 89 cases, confirmed to have poliomyelitis with residual paralysis, were enrolled in a case-control study, up to 5 matched controls being obtained for each case. The clinical efficacy for one dose of N-IPV was 36% (95% confidence interval 0%, 67%) and for two doses was 89% (95% CI 62%, 97%).
Related Concept Videos
Vaccinations
Poliomyelitis

